Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.81 |
| ▸ | NR3C2 | P08235 | 19/20 | 0.81 |
| ▸ | PGR | P06401 | 16/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5798514 | 0.92 | NR3C1 (0.77) | NR3C1NR3C2PGR | |
| SCHEMBL5801820 | 0.91 | NR3C1 (0.72) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL5798210 | 0.91 | NR3C1 (0.75) | NR3C1NR3C2PGR | |
| SCHEMBL27774884 | 0.90 | NR3C1 (0.65) | NR3C1NR3C2PGRCYP3A4KCNH2 | |
| SCHEMBL5823040 | 0.90 | NR3C1 (0.70) | NR3C1NR3C2PGR | |
| SCHEMBL291700 | 0.90 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL5775428 | 0.90 | NR3C1 (0.73) | NR3C1NR3C2PGR | |
| SCHEMBL5797139 | 0.88 | NR3C1 (0.72) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL293334 | 0.86 | NR3C1 (0.78) | NR3C1NR3C2PGR | |
| SCHEMBL5802829 | 0.84 | NR3C1 (0.74) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | claimed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| CN-101553214-A | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy | BAUSCH & LOMB (US) | 2009-10-07 | — | — | CN | disclosed |
| CN-101528208-A | Compositions and methods for treating or preventing glaucoma or its progression | BAUSCH & LOMB (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-101522196-A | Treatment of infections and their sequelae with combined isolated glucocorticoid receptor agonists and anti-infective agents | BAUSCH & LOMB (US) | 2009-09-02 | — | — | CN | disclosed |
| CN-101522187-A | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | BAUSCH & LOMB (US) | 2009-09-02 | — | — | CN | disclosed |
| CN-101484187-A | Composition comprising dissociated glucocorticoid receptor agonist and immunosuppressant for treating dry eye | BAUCH & LOMB INC (US) | 2009-07-15 | — | — | CN | disclosed |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | BAUSCH & LOMB INCORPORATED | 2008-03-13 | — | — | US | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 95/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885NR3C2 11/4885PGR 272/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885PGR 220/4885 |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885NR3C2 87/4885PGR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.